Summit Therapeutics Shares Resumed Trading. Co Raised $200M Via Institutional Offering of 22.2M Shares at $9/Share for Clinical Development of Ivonescimab
Summit Therapeutics Shares Resumed Trading. Co Raised $200M Via Institutional Offering of 22.2M Shares at $9/Share for Clinical Development of Ivonescimab
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.